Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment.


Thirty-five (34 evaluable) consecutive postmenopausal women with estrogen receptor positive (greater than or equal to 10 fmol/mg) or unknown advanced breast cancer were treated with high dose toremifene in a phase II study. All patients had progressed during prior adjuvant or palliativ antiestrogen treatment. The dose of toremifene was 240 mg per day. No… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.